BPI-361175
- Generic Name
- BPI-361175
BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Xcovery Holdings, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05393466
A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05329298
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳Xiangya Hospital of Central South University, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath